Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 11 mechanisms across 34 industry trials with a known mechanism of action.

See full pipeline →

Tyrosine Kinase 2 Inhibitor

3 trials 3 active 1 sponsor

Interleukin-17A Antagonist

14 trials 2 active 2 sponsors

Phosphodiesterase 4 Inhibitor

5 trials 2 active 1 sponsor

TNF

3 trials 1 active 1 sponsor

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

1 trials 1 active 1 sponsor

Tumor Necrosis Factor Blocker

3 trials 2 sponsors

Janus Kinase Inhibitor

1 trials 1 sponsor

Selective T Cell Costimulation Modulator

1 trials 1 sponsor

Interleukin-23 Antagonist

1 trials 1 sponsor

Interleukin-12 Antagonist

1 trials 1 sponsor

Folate Analog Metabolic Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

120 industry-sponsored trials across 37 sponsors

View full landscape →

Showing 9 of 9 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	RECRUITING	2027-11	NCT06864026
CARE ARTHRITIS LTD.	Upadacitinib 15 MG [Rinvoq]	—	RECRUITING	2028-09	NCT06454188
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2024-08-08	NCT05855967
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	COMPLETED	2021-10-26	NCT03783026
AbbVie	methotrexate (MTX)	—	COMPLETED	2019-09-23	NCT02814175
Novartis	Secukinumab 300 mg	—	COMPLETED	2018-12-05	NCT02798211
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2018-11-15	NCT03151551
Kyowa Kirin Co., Ltd.	Brodalumab 210mg SC	—	COMPLETED	2017-01-10	NCT04183881
Pfizer	—	—	COMPLETED	2011-07	NCT01147874

Showing 67 of 67 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AbbVie	Adalimumab	TNF	RECRUITING	2026-09	NCT06100744
Takeda	Zasocitinib	—	RECRUITING	2027-05-18	NCT06671483
Takeda	Zasocitinib	—	RECRUITING	2027-05-18	NCT06671496
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	RECRUITING	2028-03-21	NCT04804553
UCB Biopharma SRL	Bimekizumab	—	RECRUITING	2028-04-12	NCT06668181
Takeda	Zasocitinib	—	RECRUITING	2029-12-18	NCT07286058
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	Picankibart	—	RECRUITING	2029-12-31	NCT07295509
Bristol-Myers Squibb	Deucravacitinib	Tyrosine Kinase 2 Inhibitor [EPC]	RECRUITING	2030-03-06	NCT06869551
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	RECRUITING	2036-03-17	NCT05767047
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1314 injection	—	RECRUITING	2026-04-30	NCT06640257
UCB Biopharma SRL	bimekizumab	—	ACTIVE NOT RECRUITING	2027-03-09	NCT06506916
Sun Pharmaceutical Industries Limited	TILD sub-cutaneous (SC) injection	—	ACTIVE NOT RECRUITING	2028-12	NCT04991116
UCB Biopharma SRL	Bimekizumab	—	ACTIVE NOT RECRUITING	2026-05-25	NCT04009499
UCB Biopharma SRL	Bimekizumab	—	ACTIVE NOT RECRUITING	2026-02-06	NCT06624228
Sun Pharmaceutical Industries Limited	TILD	—	ACTIVE NOT RECRUITING	2025-06-04	NCT04314531
Bristol-Myers Squibb	Deucravacitinib	Tyrosine Kinase 2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-09-05	NCT04908202
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	ACTIVE NOT RECRUITING	2024-02-19	NCT04527380
Bristol-Myers Squibb	Deucravacitinib	Tyrosine Kinase 2 Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-02-06	NCT04908189
AbbVie	Risankizumab	—	ACTIVE NOT RECRUITING	2020-10-08	NCT03675308
AbbVie	Risankizumab	—	ACTIVE NOT RECRUITING	2020-06-22	NCT03671148
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2025-11-18	NCT06588296
Sun Pharmaceutical Industries Limited	TILD	—	COMPLETED	2025-03-26	NCT04314544
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2024-11-07	NCT03769168
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2024-10-22	NCT04632927
Bio-Thera Solutions	BAT2506	—	COMPLETED	2023-10-06	NCT05046431
Sun Pharmaceutical Industries Limited	SUNPG18_07 I (Tildrakizumab 200 mg)	—	COMPLETED	2023-09-18	NCT03552276
Novartis	AIN457	—	COMPLETED	2022-06-02	NCT04711902
Novartis	AIN457 6 mg/kg i.v.	—	COMPLETED	2022-05-17	NCT04209205
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2021-12-08	NCT03896581
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2021-08-17	NCT03895203
Pfizer	Tofacitinib	—	COMPLETED	2021-04-28	NCT03486457
Novartis	AIN457 (secukinumab)	—	COMPLETED	2020-11-10	NCT02662985
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2020-11-05	NCT04109976
Novartis	secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2020-10-07	NCT03031782
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2019-12-30	NCT02745080
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2019-12-11	NCT02771210
AbbVie	Adalimumab	TNF	COMPLETED	2019-09-26	NCT03104400
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2019-07-23	NCT03104374
Biocad	BCD-085	—	COMPLETED	2019-06-26	NCT03598751
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2019-01-08	NCT03370133
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2018-12-28	NCT03410992
Eli Lilly	Ixekizumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2018-10-30	NCT02584855
UCB Biopharma S.P.R.L.	e-Device	—	COMPLETED	2018-07-02	NCT03357471
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2018-01-11	NCT01892436
Amgen	Etanercept	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2018-01-09	NCT02376790
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2017-08-16	NCT02404350
Eli Lilly	Ixekizumab 80 mg Q4W	—	COMPLETED	2016-09-09	NCT02349295
Pfizer	Tofacitinib	—	COMPLETED	2016-04	NCT01882439
Pfizer	Tofacitinib 5 mg BID	—	COMPLETED	2015-12-18	NCT01877668
Bausch Health Americas, Inc.	210 mg brodalumab	—	COMPLETED	2015-10	NCT02024646
Bristol-Myers Squibb	Abatacept	Selective T Cell Costimulation Modulator [EPC]	COMPLETED	2015-07-14	NCT01860976
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	COMPLETED	2015-05-27	NCT01989468
Tanabe Pharma Corporation	TA-650	—	COMPLETED	2015-03	NCT01680159
Amgen	Apremilast 30 mg	—	COMPLETED	2015-02-25	NCT01925768
Kyowa Kirin Co., Ltd.	KHK4827 140mg SC	—	COMPLETED	2015-01-28	NCT02052609
Novartis	Secukinumab (75 mg)	—	COMPLETED	2014-10	NCT01392326
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	COMPLETED	2014-07-03	NCT01690299
Novartis	Secukinumab (AIN457)	—	COMPLETED	2014-05-12	NCT01752634
Amgen	Etanercept / Autoinjector A	—	COMPLETED	2013-12-18	NCT01901185
Amgen	Apremilast 20mg	—	COMPLETED	2013-02-21	NCT01307423
Amgen	Apremilast 20mg	—	COMPLETED	2012-08-21	NCT01212770
Amgen	Apremilast 20mg	—	COMPLETED	2012-07-26	NCT01212757
Amgen	Apremilast 20mg	—	COMPLETED	2012-04-27	NCT01172938
ACELYRIN Inc.	Izokibep	—	TERMINATED	2023-11-30	NCT05623345
Gilead	Filgotinib	—	TERMINATED	2021-01-19	NCT04115748
Gilead	Filgotinib	—	TERMINATED	2021-01-04	NCT04115839
Bausch Health Americas, Inc.	210 mg brodalumab	—	TERMINATED	2015-10	NCT02029495

Showing 29 of 29 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Spyre Therapeutics, Inc.	SPY002-072	—	RECRUITING	2026-10-31	NCT07148414
Merck	Tulisokibart	—	RECRUITING	2027-08-13	NCT07486960
InventisBio Co., Ltd	D-2570	—	RECRUITING	2027-08-15	NCT07315061
AbbVie	Lutikizumab	—	RECRUITING	2027-12	NCT06865105
Hansoh BioMedical R&D Company	HS-10374	—	RECRUITING	2026-04-28	NCT06176508
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQH3906 Capsule	—	NOT YET RECRUITING	2027-08	NCT07406035
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-1314 injection	—	COMPLETED	2024-06-05	NCT05055934
Takeda	NDI-034858	—	COMPLETED	2023-05-04	NCT05153148
ACELYRIN Inc.	ABY-035	—	COMPLETED	2021-10-01	NCT04713072
UCB Biopharma SRL	Bimekizumab	—	COMPLETED	2020-10-29	NCT03347110
Galapagos NV	Filgotinib	—	COMPLETED	2020-08-14	NCT03926195
Bristol-Myers Squibb	BMS-986165 Dose A	—	COMPLETED	2020-04-27	NCT03881059
Pfizer	PF-06700841	—	COMPLETED	2020-04-06	NCT03963401
Sun Pharmaceutical Industries Limited	SUNPG1623 I	—	COMPLETED	2019-03-01	NCT02980692
AbbVie	risankizumab	—	COMPLETED	2018-07-08	NCT02986373
Galapagos NV	filgotinib	—	COMPLETED	2018-03-12	NCT03101670
UCB Biopharma S.P.R.L.	Bimekizumab	—	COMPLETED	2017-11	NCT02969525
AbbVie	adalimumab	TNF	COMPLETED	2016-07-04	NCT02349451
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	COMPLETED	2016-05-31	NCT02319759
AbGenomics B.V Taiwan Branch	AbGn-168H	—	COMPLETED	2015-10	NCT02267642
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	COMPLETED	2014-11-20	NCT01988103
Novartis	AIN457A	—	COMPLETED	2012-11	NCT01169844
Inflexxion, Inc.	—	—	COMPLETED	2012-11	NCT01463189
Novartis	AIN457	—	COMPLETED	2010-12	NCT00809614
Ventyx Biosciences, Inc	Dose A VTX958	—	TERMINATED	2024-01-02	NCT05715125
Aclaris Therapeutics, Inc.	ATI-450	—	TERMINATED	2023-12-06	NCT05511519
Galapagos NV	filgotinib	—	TERMINATED	2021-06-30	NCT03320876
AbbVie	ABT-122	—	TERMINATED	2016-05	NCT02429895
Bausch Health Americas, Inc.	AMG 827 140	—	TERMINATED	2012-09	NCT01516957

Showing 15 of 15 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
UCB Biopharma SRL	Bimekizumab	—	RECRUITING	2027-05-03	NCT06888193
UCB Biopharma SRL	Bimekizumab regimen 1 iv	—	RECRUITING	2028-05-18	NCT07290036
Novartis	Secukinumab	Interleukin-17A Antagonist [EPC]	RECRUITING	2032-11-30	NCT06751238
LAPIX Therapeutics Inc.	LPX-TI641	—	RECRUITING	2025-12-15	NCT06628206
Seismic Therapeutic AU Pty Ltd	S-4321	—	NOT YET RECRUITING	2027-06	NCT07455578
selectION Therapeutics GmbH	si-544	—	COMPLETED	2025-06-23	NCT06191042
Johnson & Johnson	Ustekinumab	Interleukin-12 Antagonist [EPC]	COMPLETED	2024-01-26	NCT05252533
Bio-Thera Solutions	BAT2506 injection	—	COMPLETED	2023-06-27	NCT05332730
UCB Biopharma SRL	Pharmacokinetics of certolizumab pegol	—	COMPLETED	2023-05-23	NCT04163016
Bio-Thera Solutions	Drug: BAT2506 injection Other Names: Simponi(EU-licensed)	—	COMPLETED	2020-12-31	NCT04152759
Fresenius Kabi SwissBioSim GmbH	40 mg MSB11022	—	COMPLETED	2020-03-17	NCT04018599
Bristol-Myers Squibb	Methotrexate	Folate Analog Metabolic Inhibitor [EPC]	COMPLETED	2018-03-20	NCT03402087
UCB BIOSCIENCES, Inc.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-10	NCT02019602
UCB BIOSCIENCES, Inc.	Certolizumab Pegol	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2015-12	NCT02154425
UCB Celltech	UCB4940 40 mg	—	COMPLETED	2015-08	NCT02141763

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Psoriatic Arthritis

TNF-alpha (20)

Novel Drugs by Company (New molecular entities)

Johnson & Johnson 4 drugs

ALVOTECH USA INC 2 drugs

Amgen 2 drugs

UCB INC 2 drugs

Fresenius Kabi 2 drugs

IMMUNEX 1 drug

SAMSUNG BIOEPIS CO LTD 1 drug

AbbVie 1 drug

Viatris 1 drug

BIO-THERA SOLUTIONS LTD 1 drug

STARJEMZA

USTEKINUMAB-HMNY

BLA 2025

+8 more companies

Reformulations (5 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

SAMSUNG BIOEPIS CO LTD